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Background: Lung ischemia–reperfusion injury (LIRI) may occur in the region of the
affected lung after reperfusion therapy. Inhaled NO may be useful in treating acute and
chronic pulmonary thromboembolism (PTE) due to the biological effect property of NO.
Methods: A PTE canine model was established through selectively embolizing blood
clots to an intended right lower lobar pulmonary artery. PaO2/FiO2, the mPAP and
PVR were investigated at the time points of 2, 4, 6 hours after inhaled NO. Masson’s
trichrome stain, apoptotic pneumocytes and lung sample ultrastructure were also
investigated among different groups.
Results: The PaO2/FiO2 in the Inhaled NO group increased significantly when
compared with the Reperfusion group at time points of 4 and 6 hours after reperfusion,
mPAP decreased significantly at point of 2 hours and the PVR decreased significantly at
point of 6 hours after reperfusion. The amounts of apoptotic type II pneumocytes in
the lower lobar lung have negative correlation trend with the arterial blood PaO2/FiO2
in Reperfusion group and Inhaled NO group. Inhaled nitric oxide given at 20 ppm for
6 hours can significantly alleviate the LIRI in the model.
Conclusions: Dramatic physiological improvements are seen during the therapeutic
use of inhaled NO in pulmonary thromboembolism canine model. Inhaled NO may be
useful in treating LIRI in acute or chronic PTE by alleviating apoptotic type II
pneumocytes. This potential application warrants further investigation.
Keywords: Lung ischemia-reperfusion injury, Pulmonary thromboembolism, Apoptotic
pneumocytes, Inhaled nitric oxideIntroduction
Pulmonary thromboembolism (PTE) has been experienced by 60% of patients who die
in the hospital and it is currently the third most common cause of death in hospitalized
patients [1].
Lung ischemia–reperfusion injury (LIRI) may occur in the region of the affected lung
after the thrombolytic therapy, pulmonary embolectomy, pulmonary suction thrombec-
tomy [2-4], or the alternative interventional strategy of balloon pulmonary angioplasty
(BPA) for chronic thromboembolic pulmonary hypertension (CTEPH) [5].Clinically,
LIRI is characterized by reperfusion pulmonary edema (RPE) developing within 48 h© 2014 Deng et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://
creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
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jected to prolonged intubation for mechanical ventilation, ventilator-associated infections,
longer stays in the intensive care unit (ICU), and early postoperative mortality [6-8].
Programmed cell death (apoptosis) appears to be a significant type of cell loss in human
lungs after transplantation. A number of studies in humans demonstrate that reperfusion
after ischemia induces apoptosis in more than 20% of parenchymal lung cells (mainly type
II pneumocytes) after lung transplantation [9,10]. This cell loss might be responsible for
severe organ dysfunction [10,11]. The mechanisms related to the LIRI in PTE, especially
apoptosis of the pneumocytes, are less deeply understood as that of lung transplantation
[12]. Because of organization and recanalization channels within the chronic thrombus,
the ischemic changes of chronic PTE may be less when compared to the ischemic changes
brought about by deliberate/experimental ligation or other inert blockage. At present,
little is known about the relation between LIRI and the induction of apoptosis on pneu-
mocytes in acute or chronic PTE.
The treatment with inhaled nitric oxide(NO) has been advocated to improve RPE
after pulmonary suction thrombectomy and pulmonary thromboendarterectomy for
chronic PTE [13-15]. However, this treatment does not work in all patients. Studies
examining the inhalation delivery of NO in experimental and clinical applications have
shown discrepant results; some show to mitigate LIRI including its antioxidant properties
and its cytoprotective abilities including attenuating apopotosis [16-18], whereas others
demonstrate detrimental or neutral effects [19,20] and the detailed mechanisms remain to
be understood.
We have successfully established a reproducible modified experimental canine PTE
model with autologous cylinder blood clots selectively embolized into any intended
lobar artery with guidance of Swan-Ganz float catheter under X-ray fluoroscopy. This
model may mimic the pathological changes of chronic PTE and the location of
thrombus is similar to proximal type of CTEPH [21]. In PTE, the pulmonary lower
lobar artery is more commonly involved due to a more extensive circulation [22].
Therefore, we aimed at precisely embolizing the right lower pulmonary lobar artery.
Two weeks later after selective embolization, we performed embolectomy for reperfusion
as to examine the LIRI changes, especially apoptotic pneumocytes.
Results
1. Three main types of reddish brown thrombus with irregular surface were shown
after embolectomy from lower pulmonary lobar artery. The thrombi were either
multiple fragmentary segments (Figure 1A, C) or a complete elongated strip with
multiple pink granulation-like protrusions and multiple branches corresponding to
the pulmonary artery configuration (Figure 1B).
2. The macroscopic pathology of the lung in the four groups was shown in Figure 2.
Sham group showed the pink lung appearance with a little congestion (Figure 2A).
Ischemia group showed reddish-greyish color lung with some collapsed appearance
(Figure 2B). Reperfusion group showed reddish lung with congestion and swelling
(Figure 2C), some parts of which with dark red areas that indicate bleeding. Inhaled
NO group showed pink color lung with congestion and swelling, some small parts
of which with bright red to dark red areas that indicate bleeding (Figure 2D). The
Figure 1 The thrombus is shown after embolectomy from a lower pulmonary lobar artery. The
thrombi were either multiple fragmentary segments (Figure 1A, C) or a complete elongated strip with
multiple pink granulation-like protrusions and multiple branches corresponding to the pulmonary artery
branches (Figure 1B).
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than that in reperfusion group.
3. The arterial blood PaO2/FiO2 and hemodynamic parameters (HR, mPAP, CO, PVR)
in four groups are shown in Table 1.






(white aIn Sham group and Ischemia group, there was no significant difference on the
PaO2/FiO2 and hemodynamic parameters at different time points after surgical
procedures (P > 0.05).
In the Reperfusion group, the heart rates at the time points of 2, 4, 6 hours after
embolectomy were significantly faster than baseline, most obviously at the time
point of 6 hours after reperfusion (175 ± 8 beats/min vs. 155 ± 5 beats/min,
P <0.05). The PaO2/FiO2 decreased significantly at the time points of 2, 4,
6 hours after reperfusion than that of baseline, most obviously at point 4 hours
after reperfusion (287.90 ± 54.84 mmHg vs. 410.40 ± 28.36 mmHg, P <0.05). The
mPAP increased significantly at point 2 hours after reperfusion (24 ± 4
mmgHg vs. 17 ± 3 mmHg, P <0.05). At the time point of 4 hours after
reperfusion, mPAP increased but without significant difference (P > 0.05)2 The gross appearance of the lung in the four groups. A. The Sham group showed pink lung
ittle congestion (white arrow). B. The Ischemia group showed a reddish-gray lung with some collapsed
nce (white arrow). C. The Reperfusion group showed a reddish lung with congested and swollen
nce (white arrow) with some dark red appearance indicating bleeding. D. The Inhaled NO group
a somewhat similar but less congested and swollen lung appearance as the reperfusion group
rrow).
Table 1 HR, arterial blood gases and hemodynamic parameters at each time point after
surgical procedures in four groups are shown (n = 6 in each group) x  sð Þ
0 h 2 h 4 h 6 h
HR (beats/min)
Group 1 152 ± 5 155 ± 7 154 ± 8 157 ± 8
Group 2 155 ± 7 158 ± 6 156 ± 9 160 ± 7
Group 3 155 ± 5 162 ± 5*# 168 ± 9*#Δ 175 ± 8*
Group 4 154 ± 6 160 ± 6 168 ± 8*Δ 167 ± 7*
pH
Group 1 7.32 ± 0.06 7.33 ± 0.03 7.29 ± 0.10 7.31 ± 0.01
Group 2 7.25 ± 0.04 7.26 ± 0.04 7.24 ± 0.03 7.21 ± 0.01
Group 3 7.25 ± 0.11# 7.11 ± 0.18 7.23 ± 0.05 7.15 ± 0.14#
Group 4 7.27 ± 0.05 7.18 ± 0.19 7.13 ± 0.11# 7.15 ± 0.20
PaCO2 (mmHg)
Group 1 36.88 ± 6.06 41.52 ± 12.41 40.18 ± 13.86 40.84 ± 10.62
Group 2 38.88 ± 6.66 42.52 ± 12.41 42.18 ± 10.86 44.84 ± 7.62
Group 3 41.43 ± 9.51 56.77 ± 22.75 49.15 ± 14.03 47.48 ± 14.15
Group 4 38.88 ± 6.66 48.52 ± 22.41 45.18 ± 13.86 47.84 ± 17.62
PaO2/FiO2(mmHg)
Group 1 484.42 ± 28.34 475.50 ± 20.80 543.45 ± 61.56 423.20 ± 23.20
Group 2 430.95 ± 28.37 428.75 ± 37.50 431.25 ± 39.24◆ 435.00 ± 31.62◆
Group 3 410.40 ± 28.36 335.55 ± 29.29*#Δ 287.90 ± 54.84*#Δ 292.83 ± 60.34*#Δ
Group 4 441.43 ± 24.26 371.87 ± 20.35*# 368.83 ± 55.29*#Δ◆ 380.63 ± 56.83◆
MPAP (mmHg)
Group 1 14 ± 1 14 ± 1 13 ± 3 12 ± 1
Group 2 16 ± 2 15 ± 2 14 ± 1 15 ± 2
Group 3 17 ± 3 24 ± 4*#Δ 22 ± 4#Δ 18 ± 4#§
Group 4 17 ± 4 19 ± 3#Δ◆ 20 ± 2#Δ 15 ± 2#§
CO(l/min)
Group 1 2.95 ± 0.32 2.84 ± 0.24 2.84 ± 0.69 2.86 ± 0.53
Group 2 2.60 ± 1.00 2.62 ± 1.04 2.62 ± 1.08 2.73 ± 1.03
Group 3 2.88 ± 1.04 2.60 ± 1.14 2.71 ± 1.28 2.63 ± 1.19
Group 4 3.01 ± 0.64 2.62 ± 0.26 3.17 ± 0.54 3.20 ± 0.55
PVR(dyne.s.cm−5)
Group 1 164.24 ± 45.61 200.94 ± 59.54 140.46 ± 55.84 171.59 ± 38.72
Group 2 301.25 ± 96.77# 253.68 ± 99.09 299.52 ± 92.64# 271.66 ± 93.89#
Group 3 373.20 ± 89.09# 601.01 ± 92.33*#Δ 435.88 ± 99.63# 327.09 ± 96.66#§
Group 4 335.88 ± 63.46# 474.67 ± 87.91*# 335.93 ± 43.84# 239.86 ± 53.26*◆§
Note: Group 1: Sham group, Group 2: Ischemia group, Group 3: Reperfusion group, Group 4: Inhaled NO group. * and §
P < 0.05 for the comparison with the parameters recorded at the time point before reperfusion and 2 hours after
reperfusion within the same group, respectively. At the same time point among different groups,#P < 0.05 for the
comparison with the Sham group,Δ P < 0.05 for the comparison with the Ischemia group,◆ P < 0.05 for the comparison
with the Reperfusion group.
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PVR increased significantly at time point of 2 hours after reperfusion when
compared with that of baseline (601.01 ± 92.33 dyne.s.cm-5 vs. 373.20 ± 89.09
dyne.s.cm-5, P <0.05), then decreased gradually to the baseline level.
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of 2, 4 hours after reperfusion than that of baseline, most obviously at point 4 hours
after reperfusion (368.83 ± 55.29 mmHg vs. 441.43 ± 24.26 mmHg, P <0.05) and
increased gradually at the time point of 6 hours after reperfusion without
significant difference when compared with the baseline (380.63 ± 56.83 mmHg
vs. 441.43 ± 24.26 mmHg, P > 0.05). The mPAP increased at time point of 2
and 4 hours after reperfusion while at the point of 6 hours it decreased to the level
much lower than the point of 4 hours (15 ± 2 mmHg vs. 20 ± 2 mmHg, P <0.05).3.2 The parameters at each time point after surgical procedures between the
different groups were compared.
HR at the time point of 4 hours after embolectomy in Reperfusion group was
significantly faster than the Sham group (168 ± 9 beats/min vs. 154 ± 8 beats/
min, P < 0.05) and the Ischemia group (168 ± 9 beats/min vs. 156 ± 9 beats/min,
P < 0.05).
The PaO2/FiO2 in the Reperfusion group decreased significantly at point 4
and 6 hours after embolectomy when compared with the Ischemia group
(287.90 ± 54.84 mmHg vs. 431.25 ± 39.24 mmHg) and (292.83 ± 60.34 mmHg
vs. 435.00 ± 31.62 mmHg), respectively (both P < 0.05). The PaO2/FiO2
in the Inhaled NO group increased significantly when compared with the
Reperfusion group at points 4 and 6 hours (368.83 ± 55.29 mmHg vs.
287.90 ± 54.84 mmHg) and (380.63 ± 56.83 mmHg vs. 292.83 ± 60.34 mmHg
(both P < 0.05).
The mPAP in Reperfusion group increased significantly at point 2 and 4 hours
after reperfusion when compared with the Ischemia group (24 ± 4 mmHg vs.
15 ± 2 mmHg) and (22 ± 4 mmHg vs. 14 ± 1 mmHg), respectively (both P < 0.05).
In the Inhaled NO group, when compared with the Reperfusion group, mPAP
decreased significantly at point 2 hours after reperfusion (19 ± 3 mmHg vs. 24 ±
4 mmHg, P < 0.05); while at points 4 and 6 hours after reperfusion, a decreasing
mPAP trend was noted but without significant difference (P > 0.05).
PVR in Reperfusion group increased significantly at point 2 hours after
embolectomy when compared with Ischemia group (601.01 ± 92.33 dyne.s.cm-5
vs. 253.68 ± 99.09 dyne.s.cm-5, P < 0.05). In Inhaled NO group, at time point of
6 hours after reperfusion with inhaled NO, the PVR decreased significantly
when compared with that in the Reperfusion group (239.86 ± 53.26 vs.
327.09 ± 96.66, P < 0.05).
4. Pathology stained by Masson’s trichrome stain was shown in different groups.
The alveolar structure with some exudation in the right lower lung of the Sham
group was shown in Figure 3A. Some collapsed alveolar structures, thickened
alveolar septa, and collagen fibers stained blue and a few exudative cells in the
alveolar space were shown in the Ischemia group (Figure 3B). Incomplete and
destructed alveolar structure with a large number of exudative cells and exudation
were seen within the alveolar spaces in the Reperfusion group (Figure 3C). Similar
incomplete and destructed alveolar structures with exudative cells and exudation
were shown in the Inhaled NO group, but much less when compared with the
Reperfusion group (Figure 3D).
Figure 3 Pathology stained by Masson's trichrome stain was shown in different groups. A. The
alveolar structure with some exudation in the right lower lung was shown in the Sham group. B. Some
collapsed alveolar structures, atelectasis with thickened alveolar septa (white arrow), collagen fibers, and a
few exudative cells in the alveolar space were shown in the Ischemia group. C. Incomplete and destructed
alveolar structure with a large number of exudative cells and exudation (white arrow) were seen within the
alveolar spaces in the Reperfusion group. D. Alveolar structures with exudative cells and exudation were
shown in the Inhaled NO group, but less when compared with the Reperfusion group (white arrow).
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amounts of apoptotic type II pneumocytes and PaO2/FiO2.
The apoptotic pneumocytes were observed in the segment distal the clot. No
apoptotic cell was detected in the Sham group (Figure 4A). In the Ischemia group,
some apoptotic pneumocytes (1 ± 1 pneumocytes/5 fields, 400’) were revealed by
TUNEL method (Figure 4B). Six hours after surgery, the number of apoptotic
pneumocyte in Reperfusion group was more than that of the Ischemia group
(5 ± 1 pneumocytes/5 fields vs. 1 ± 1 pneumocytes/5 fields, Figure 4C). In the
Inhaled NO group, the number of apoptotic pneumocyte was also much more than
the Ischemia group (5 ± 2 pneumocytes/5 fields vs. 1 ± 1 pneumocytes/5 fields,
P < 0.05, Figure 4D) The amounts of apoptotic type II pneumocytes in the lower
lobar lung have negative correlation trend with the arterial blood PaO2/FiO2 in
Reperfusion group and Inhaled NO group.
6. Lung sample ultrastructure was evaluated by electron microscopy.
Lung ultrastructural architecture was normal in the Sham group and type II
pneumocytes did not show evidence of apoptosis with normal lamellar bodies,
mitochondria, tight junction and microvilli (Figure 5A). The perinuclear gap in the
type II pneumocytes was widened and showed early stage apoptosis in the Ischemia
group (Figure 5B). Swelling of lamellar bodies in some type II pneumocytes and
nuclear membrane blebbing were shown in the Inhaled NO group (Figure 5C, D).
Apoptosis was indicated by more extensive nuclear shrinkage, chromatin condensationFigure 4 The apoptotic pneumocytes were observed in the segment distal the clot. A. There were no
apoptotic cells detected on slides in Sham group. B. In the Ischemia group, the slides revealed some
apoptotic pneumocytes shown by TUNEL (white arrow). C. In the Reperfusion group, the number of
apoptotic pneumocytes was much more than Ischemia group (white arrow). D. In the Inhaled NO group,
there were also many apoptotic pneumocytes (white arrow).
Figure 5 Lung sample ultrastructure was evaluated by electron microscopy. A. The ultrastructural
architecture of type II pneumocytes as evaluated by Electron Microscopy with normal lamellar bodies,
mitochondria, tight junction, and microvilli was normal in Sham group. B. The perinuclear gap in the type II
pneumocytes was widened and showed early stage of apoptosis in the Ischemia group (white arrow head).
C, D. Swelling of lamellar bodies (black arrow) in some type II pneumocytes and nuclear membrane
blebbing (white arrow head) were shown in the Inhaled NO group. E. Apoptosis was indicated by more
extensive nuclear shrinkage, chromatin condensation and margination (white arrow head), whereas plasma
membrane and intracellular organelles such as lamellar bodies showed degenerative changes (black arrow)
but had an intact surface in the Reperfusion group. F. The type II pneumocyte with lamellar bodies swelling
(black arrow), cytoplasmic vacuolation, and irregular nuclear shed into the alveolar space in Reperfusion
group.
Deng et al. Theoretical Biology and Medical Modelling 2014, 11:36 Page 7 of 14
http://www.tbiomed.com/content/11/1/36and margination, whereas plasma membrane and intracellular organelles such as
lamellar bodies showed degenerative changes but had intact surface in the Reperfusion
group (Figure 5E). Furthermore, the type II pneumocyte had lamellar bodies swelling,
cytoplasmic vacuolation, and irregular nuclei shed into the alveolar space in Reperfusion
group (Figure 5 F).Discussion
Previously, we have successfully established a modified canine PTE model. This model
has mimicked the pathological changes of chronic PTE. Due to a precise embolization
into the intended right lower pulmonary artery, it is convenient for us to perform embol-
ectomy for investigating the effects of the LIRI in the model. The three types of reddish
brown thrombus enucleated by embolectomy from the involved pulmonary lobar artery
revealed the irregular surface with multiple pink granulation-like protrusions and multiple
branches corresponding to the lobar artery branches. Generally, during ischemia-
reperfusion injury in systemic vascular beds, the vascular response appears to occur
in at least two phases: (1) ischemia, which is associated with lack of oxygen, cell
damage, and activation of cytotoxic enzymes, and (2) reperfusion, which is associated
with formation of reactive oxygen intermediates, platelet and neutrophil activation,
endothelial cell injury, increased vascular permeability, cytokine activity, and complement
activation [23]. The multiple recanalization channels within the organized thrombus,
which are associated with the persistent period of embolism, is significantly correlated to
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stain in the ischemia group, LIRI results in atelectasis, fibrosis and moderate inflammation
characterized by a ‘chronic’ fibroproliferative state, including infiltration, collagen depos-
ition and pulmonary remodeling [25]. The microenvironment provided by the unresolved
clot and inflammatory cells may stimulate this erroneous cell proliferation and injure cells
[26,27]. Hypoxic conditions can enhance the production of inducible nitric oxide synthe-
tase (NOS) that may increase oxidant radical byproducts, such as the peroxynitrite anion,
and lead to reactive oxygen species (ROS)-type cellular injury [28]. ROS have diverse
actions on pulmonary tissue including smooth muscle contraction, interaction with redox
enzymes, cell proliferation, and gene transcription [29]. Apoptosis is a genetically con-
trolled programmed cell death resulting from activation of the intrinsic (mitochondrial)
and extrinsic (death receptor) pathways; it can be triggered by mechanical injury and
exposure to certain environmental conditions such as hypoxic conditions [30]. Governing
such pathways to the lung apoptosis after ischemia–reperfusion can open new vistas for
reducing the severity of LIRI [31]. Apoptosis is characterized morphologically by nuclear
condensation and shrinkage followed by fragmentation of nuclear chromatin without
typical inflammation, which have been showed by TUNEL in our study.
With re-establishment of blood flow, the injury elicited by reperfusion can be more
severe than that caused by ischemia per se; the injury may also result from the com-
bined effects of ischemia and reperfusion [24]. The most important factor complicating
the early postoperative period after pulmonary thromboendarterectomy is RPE [32].
This injury is due primarily to mechanisms that cause alveolar epithelial cell damage
and increase pulmonary vascular permeability, as have been shown by the Masson’s
trichrome stain of the pathological sections. Thus, the injury is associated with impaired
gas exchange (exemplified by the decreased PaO2/FiO2) from increased edema formation
and surfactant inactivation Carrico index (ratio of arterial PO2 (mmHg)/inspired O2
(fraction)) is the most useful measure of pulmonary oxygenation in clinical practice
and stands for the objective index for the oxygenation. Therefore, in our model, the
PaO2/FiO2 decreased significantly at the time points of 2, 4, 6 hours after reperfusion
than that of baseline as LIRI occurs in patients endarterectomized and reperfused [33].
The accepted theory for reperfusion lung injury is primarily also based on the generation
of ROS upon reperfusion, causing cellular damage and apoptosis [30,34]. Even a low num-
ber of apoptotic cells at a given time point may indicate a substantial rate of cell loss [35].
A direct correlation between the degree of lung apoptosis after lung ischemia–reperfusion
and pulmonary dysfunction remains controversial. When sufficient injury is inflicted
on a cell, there are two major types of cell death that can occur: necrosis and apop-
tosis. Necrosis is a form of irreversible cell death accompanied by the loss of cell
membrane integrity and ion pump damage. The clinical manifestations of RPE occurring
after interventions for PTE are similar to RPE after lung transplantation [5-8]. Of particu-
lar importance after lung transplantation is severe life-threatening graft dysfunction that
occurs in up to 30% of patients; this is related to LIRI [36]. A study concluded that a
significant number of pneumocytes undergo apoptosis after reperfusion, that the peak in
the number of apoptotic pneumocytes occurs as early as 2 hours after reperfusion in the
transplanted rat lung [37]. In our experimental model, apoptotic pneumocytes induced by
LIRI were much more than those in the Ischemia group. These apoptotic pneumocytes
were confirmed by EM ultrastructural evaluation to be mainly type II pneumocytes, with
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as cardiopulmonary bypass [11,38].
Inhaled NO may be useful in treating acute and chronic pulmonary embolism due to
the biological vasodilatory effect property of NO [13,39,40]. In our experimental model,
when inhaled NO at 20 ppm was administered, the PaO2/FiO2 decreased significantly
at the time points of 2, 4 hours after reperfusion by embolectomy and, at the time point
of 6 hours after reperfusion, increased gradually to the baseline mainly due to the
improvement in V/Q matching [3,14,15]. When compared with the Reperfusion group,
the PaO2/FiO2 increased significantly after inhaling 20 ppm NO for 4 or 6 hours, one
of the mechanisms relating to elevating inducible nitric oxide synthase (iNOS) expression,
and NOS activity in the lungs [41]. After inhaling NO for 6 hours, the mPAP decreased to
the level much lower than that of the 4 hours and the PVR decreased significantly possibly
due to the regional vasodilatation effect of inhaled NO [3,14,15] when compared with that
in the Reperfusion group , which are in accordance with the clinical investigations of RPE
after pulmonary suction thrombectomy and pulmonary thromboendarterectomy for
chronic PTE.
In addition, the amounts of apoptotic type II pneumocytes have negative correlation
trend with the arterial blood PaO2/FiO2 because the apoptotic pneumocytes are of
insufficience for the surfactant secretion, preventing lung collapse, improving oxygenation.
These findings are in accord with a randomized controlled clinical study on PTE, lung
transplantation and the mechanisms [30,42]. The mechanisms of injury may involve neutro-
phil activation, oxygen radicals, cytokines, complement, arachidonic acid derivatives, platelet
activating factor [43]. The LIRI can be effectively blunted by the reduction of macrophage-
dependent injury by gadolinium while inhaled NO also will attenuate injury by reducing
pulmonary hypertension and minimizing neutrophil sequestration [44]. Study has also
found that inspired NO promoted the integrity of pulmonary endothelium, increased
the vascular density and alleviated the lung histological injury compared to ARDS by aug-
menting the mRNA expression of Endothelial Progenitor Cells (EPC) surface markers
CD34 and CD133 in lung tissue [45].
Studies suggest that inhaled NO can be either protective or toxic to the lung depending
on the dose, timing, duration of NO administration, source of NO and the local re-dox
environment; these indicate that there is a narrow therapeutic window for nitric oxide
applications [16,46,47]. Investigations have shown that the maximum protective effect is
achieved with NO concentrations between 10 and 20 ppm [48]. Inhaled NO at doses
of 15–20 ppm is routinely given for the first 4 h postoperatively and gradually with-
drawn [49].
However, currently, no randomized controlled studies have recommended the routine
use of inhaled NO in lung surgery of transplantation or PTE [50]. Therefore, further
studies may focus on the molecular interactions among apoptotic factors in LIRI
[11,51,52].
Conclusions
Dramatic physiological improvements are seen during the therapeutic use of inhaled
NO in pulmonary thromboembolism canine model. Inhaled NO may be useful in treating
LIRI in acute or chronic PTE by alleviating apoptotic type II pneumocytes. This potential
application warrants further investigation.
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Animals and study design
Animal procedures were approved by the Fujian Medical University Institutional Animal
Care and Use committee and all experiments were conducted in accordance with the
Guide for the Care and Use of Laboratory Animals.
A total of 24 healthy mongrel canines (weight, 20 ± 1.8 kg) were randomly divided
into four groups: In the Sham group (Group 1, n = 6), the procedures were the same as
in the other groups, except that, instead of the autologous cylinder blood clots, 0.9%
NaCl was infused into the canine right lower pulmonary lobar artery. The remaining
18 canines underwent selective embolization. That is, twenty milliliters of autologous
blood extracted from the canine’s saphenous vein using a 20 ml syringe were rapidly
injected into three segmental cylinder tubes of pliable medical sterile intravenous trans-
fusion polyvinyl chloride(PVC) with length of 7 cm, inner diameter of 4 mm (the tube
was named as tube I) to form the cylinder autologous blood clots at room temperature.
Eight hours later, all blood clots were placed into a sterile container with 37°C saline
for later use. Then the right external jugular vein was dissected and cannulated with a
7 F sheath. A Swan-Ganz float catheter (Edwards Lifesciences Llc, One Edwards Way
Irvine,CA92614) was used to guide another PVC tube with the length of 40 cm, inner
lumen diameter of 5 mm (the tube was named as tubeII) to float selectively into the
right lower pulmonary artery under X-ray fluoroscopic monitoring. Then, the Swan-
Ganz catheter was extracted out from the inside of the tubeII and the three segmental
autologous cylinder blood clots induced ex vivo with 7 cm long and 4 mm wide were
selectively injected into the right lower pulmonary lobar artery through the PVC tubeII
lumen. Two weeks later, the 18 canines were subdivided into 3 groups. The Ischemia
group (Group 2, n = 6) underwent identical surgical procedures except for embolectomy
and were observed for 6 hours. The Reperfusion group (Group 3, n = 6) underwent em-
bolectomy for reperfusion in the right lower artery and were observed for 6 hours after
embolectomy. The Inhaled NO group (Group 4, n = 6) underwent a process similar to the
reperfusion group but with additional administration of inhaled NO at 20 ppm for 6 hours
through mechanical ventilation.
Preparing for four experimental PTE canine models and embolectomy
Preparing the animal models before embolectomy
Two weeks after embolization, the PTE canine was anesthetized with 5 ml of intravenous
propofol, intraperitoneal injection of 0.5 ml/kg dosage of 3% sodium pentobarbital.
Endotracheal intubation followed and they were subsequently connected to Servo900C
(SIEMENS company, Germany) with volume controlled ventilation (VCV), tidal volume
of 15 ml/kg, inspired oxygen concentration of 40%, respiratory rates of 20 breaths/min,
inspiratory time of 25%, inspiratory pause time of 10% and positive end-expiratory pressure
(PEEP) of 3 cmH2O. A 7-F double-lumen Swan-Ganz thermistor catheter (Edwards
Swan-Ganz, Baxter Healthcare Corporation, Deerfield, IL) was introduced into the pul-
monary artery through the left external jugular vein. The Swan-Ganz was connected to a
pressure transducer and a multi-channel signal analysis system (Shanghai Alcott Biotech,
China) for direct measurement of cardiac output (CO) by thermodilution, mean pulmon-
ary arterial pressure (mPAP), pulmonary artery wedge pressure (PAWP). Pulmonary
vascular resistance was calculated accordingly (PVR = (mPAP-PAWP)/CO) × 80). A
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arterial blood pressure (mBP) and heart rate (HR), and for periodic collection of
arterial blood for analysis of arterial PaO2/FiO2, oxygenation index (OI), carbon
dioxide and pH.
Embolectomy for reperfusion and mechanical ventilation with inhaled NO
A right thoracotomy was performed through the fifth intercostal space. The right lower
pulmonary lobe was mobilized by dividing the pulmonary ligament and the hilar structures
were then dissected free. By clamping the right lower pulmonary artery hilum, Fogarty
arterial embolectomy was performed according to the exact location of the thrombus as
we had previously known. Anastomosis of the lower pulmonary artery was performed
with non-absorbable 5–0 running sutures. Then, the lower pulmonary artery was
unclamped and observed for reperfusion changes for 6 hours.
In the Inhaled NO group, NO delivery device (SensorNOx, SensorMedics Co. Yorba
Linda, CA) was introduced into the downstream of the humidifier through the inspiratory
limb of the respiratory circuit after the embolectomy. NO was administered at a concen-
tration of 20 ppm, starting immediately after initiating reperfusion and continuing for
6 hours during the reperfusion period. The concentrations of NO and NO2 were deter-
mined in a continuous fashion by the SensorNOx delivery device, using electrochemical
cell analysis. NO2 levels did not exceed 3 ppm.
A chest tube was inserted and the thoracotomy closed. Intravenous injection of
100U/kg heparin was performed after every surgical procedure. Hemodynamic parameters
were measured at baseline (at the time point of 0 hour) and at the time points of 2, 4 and
6 hours after surgical procedures. Each animal was covered during the experimental period
to prevent hypothermia.
The animals were killed by exsanguination
The lung was removed from each animal for observation. The lung distal the clot were
then fixed in 10% formalin and examined accordingly.
Masson’s trichrome stain The formalin-fixed lung tissues were embedded in paraffin,
cut into 4-mm-thick tissue slices and were stained by Masson’s trichrome according to
the instructions of the company (Sigma-aldrich Shanghai Company, USA).
TUNEL TUNEL was done according to the manufacturer’s instructions (R&D Systems
China (Shanghai) Company, USA) for detection of apoptosis. The slides were analyzed
by a blinded pulmonary pathologist.
TUNEL-positive pneumocytes were counted at 400’ in 100 microscopic fields per
lung lobe. Only the cells lining the alveolar wall with positive nuclear and no cytoplasmic
staining were regarded as apoptotic pneumocytes. Those found within the interstitium or
in the alveoli were not counted.
Ultrastructure Small pieces of fresh tissue were immersed in universal fixative (1%
glutaryl-aldehyde, 4% paraformaldehyde, pH 7.4) immediately after biopsy, post fixed in
2% osmium tetroxide, dehydrated in graded acetones, and embedded in an Epon-Araldite
mixture (Fisher Scientific Corp., Toronto, Ontario, Canada). Selected blocks were
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citrate. The grids were examined for pneumocytes in a Philips 208 s electron micro-
scope (N.V. Philips, Gloeilampenfarbrieken, Eindhoven, Netherlands).
Statistical analysis
SPSS 11.0 software was used in statistical analysis. Numerical parameters with normal
Gaussian distribution (According to Kolmogorov-Smirnov test) were expressed as
mean ± 1 standard deviation x  sð Þ . The differences of measured parameters among
different time point after surgery within same group were analyzed by Repeated Measures
ANOVA and the differences between groups by ANOVA. Pearson Correlation Coefficient
was used for analyzing the correlation between two variables. P value <0.05 was consid-
ered as significant differences.
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